Table 2.
Selection of recent publications assessing HSP60 as a biomarker in cancers.
| Sample type | Cancer type | Total number of samples | Assay | Finding/claim (References) |
|---|---|---|---|---|
| Biopsy | Prostate | 107 patients | WB; IHC | HSP60 is overexpressed in tumors and strongly associated with prognostic clinical parameters (Castilla et al., 2010) |
| Tissue | Cervical | 20 patients; 20 controls | 2-DE; RT-PCR; WB | Increased HSP60 expression (Hwang et al., 2009) |
| Tissue | Prostate | 289 patients | IHC; TMA | HSP60 overexpression was correlated with both biochemical recurrence and Gleason score (Glaessgen et al., 2008) |
| Tissue | Bladder | 42 patients; 10 controls | IHC | HSP60 low expression levels correlated with higher tumor stage. Loss of HSP60 expression was correlated with tumor infiltration (Lebret et al., 2003) |
| Tissue | Breast | 149 patients | IHC; TMA | No association was found between HSP60 and prognosis (Sebastiani et al., 2006) |
| Tissue | Colorectal | 44 patients | cDNA microarray; IHC | A significant association of HSP60 with tumor differentiation and pT stage was observed (Mori et al., 2005) |
| Tissue, cell line | Prostate | 120 patients; 60 controls | IHC; WB | No correlation was found between levels of HSP60 expression and phenotypic behavior of individual primary prostatic cancers (Cornford et al., 2000) |
| Tissue | Breast | 101 patients; 13 controls | WB; IHC | Increased expression of HSP60 compared with controls. HSP60 correlated with patient overall survival (Isidoro et al., 2005) |
| Tissue | HCC | 38 patients | IHC, DI | Expression of HSP60 decreased during hepatocarcinogenesis (Lim et al., 2005) |
| Serum, tissue, cell line | Breast; ovarian; prostate; ductal carcinoma | 147 patients; 93 controls | ELISA; 2-DE; WB; RT-PCR; IHC | HSP60 was overexpressed during the first steps of breast carcinogenesis (Desmetz et al., 2008) |
| Serum cell line | Breast | 40 patients; 42 controls | IHC; MALDI–TOF–MS; 2-DE | Significantly higher level of autoantibodies against HSP60 in breast cancer patient sera (Hamrita et al., 2008) |
Techniques are: 2-DE, two-dimensional gel electrophoresis; DI, dot immunoblot; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemical analyses; MALDI–TOF–MS, matrix-assisted laser desorption/ionization – time-of-flight – mass spectrometry; RT-PCR, reverse transcription polymerase chain reaction; TMA, tissue microarray; WB, western blot.